Kun Mu

Kun Mu

Auto-generated profile, based on publicly available information

Kun Mu

Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, China; Department of Pathology, Qilu Hospital of Shandong University, Jinan, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXu Li
Xu Li
SZShu Zhuo
Shu Zhuo
TZTing Zhuang
Ting Zhuang
YCYong Suk Cho
Yong Suk Cho
GWGuojin Wu
Guojin Wu
JJJin Jiang
Jin Jiang
Hippo signaling restricts tissue growth by inhibiting the transcriptional effector YAP. Here we uncover a role of Hippo signaling and a tumor suppressor function of YAP in estrogen receptor positive (ER+) breast cancer. We find that inhibition of Hippo/MST1/2 or activation of YAP blocks the ERα transcriptional program and ER+ breast cancer growth. Mechanistically, the Hippo pathway transcription factor TEAD physically interacts with ERα to increase its promoter/enhancer occupancy whereas YAP inhibits ERα/TEAD interaction, decreases ERα occupancy on its target promoters/enhancers, and promotes ERα degradation by the proteasome. Furthermore, YAP inhibits hormone-independent transcription of ERα gene (ESR1). Consistently, high levels of YAP correlate with good prognosis of ER+ breast cancer patients. Finally, we find that pharmacological inhibition of Hippo/MST1/2 impeded tumor growth driven by hormone therapy resistant ERα mutants, suggesting that targeting the Hippo-YAP-TEAD signaling axis could be a potential therapeutical strategy to overcome endocrine therapy resistance conferred by ERα mutants.

15 August 2013 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
SLShuo Liang
Shuo Liang
KMKun Mu
Kun Mu
YWYan Wang
Yan Wang
ZZZhiqiang Zhou
Zhiqiang Zhou
JZJuan Zhang
Juan Zhang
TZTingguo Zhang
Tingguo Zhang
Purpose: Alteration of CyclinD1 was suggested to relate with development of endometrial carcinogenesis before, however CyclinD1 expression is not well defined in endometrial hyperplasia lesions. We checked the relationship between its expression and clinic-pathological variables of endometrial lesions to explore the possibility for CyclinD1 as a potential diagnostic and prognostic marker. Methods: Cyclin D1 immunohistochemical analysis (IHC) was used to evaluate 201 fixed, paraffin-embedded endometrial samples which included simple hyperplasia (n = 27), atypical complex hyperplasia (ACH) (n = 41), endometrioid carcinoma (n = 103), endometrial serous carcinoma (ESC) (n = 21) and clear cell carcinoma (CCC) (n = 9). A breast cancer with known CyclinD1 expression was selected as a positive control in each immunohistochemistry run. We also performed follow-up study to estimate patients’ prognosis. Results: CyclinD1 was significantly overexpressed in atypical complex hyperplasia (ACH), endometrioid carcinoma and clear cell carcinoma (CCC). The positive signaling of CyclinD1 was showed less than 40% in simple hyperplasia and endometrial serous carcinoma (ESC). The high expression of CyclinD1 was observed in metastasis carcinoma group more significantly than non-metastasis carcinoma group. Kaplan Meier analysis demonstrated that patients with high CyclinD1 expression had an obviously poor prognosis than patients without CyclinD1 staining (p < 0.05). Moreover, according to multivariate Cox regression analysis, CyclinD1 expression, as crucial as metastasis, was a risk marker for overall survival rate. Conclusion: CyclinD1 exhibited a promising potential to predict the prognosis of patients with endometrial carcinoma. However, the statistical analysis demonstrated that CyclinD1 exhibited a poor ability to differentiate neoplastic lesions from non-neoplastic lesions; thus, the application of CyclinD1 only is not so credible for differentiation between benign and malignant lesions. Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1871063048950173.

5 September 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
XZXingchen Zhou
Xingchen Zhou
JZJunyong Zhang
Junyong Zhang
HYHaiqin Yun
Haiqin Yun
RSRanran Shi
Ranran Shi
YWYan Wang
Yan Wang
YLYou Mie Lee
You Mie Lee
Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration

19 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TZTing Zhuang
Ting Zhuang
SYSifan Yu
Sifan Yu
LZLichen Zhang
Lichen Zhang
HYHuijie Yang
Huijie Yang
XLXin Li
Xin Li
JZJian Zhu
Jian Zhu
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Ting Zhuang1, 2, *, Sifan Yu1, 2, 3 *, Lichen Zhang1, 2, 4 *, Huijie Yang1, 2, Xin Li1, 2, Yingxiang Hou1, 2, Zhenhua Liu1, 2, 5, Yuanyuan Shi1, 2, Weilong Wang6, 7, Na Yu6, 7, Anqi Li1, 2, 8, Xuefeng Li9, Xiumin Li6, 7, Gang Niu10, 11, 12, Juntao Xu10, 11, 12, Muhammad Sharif Hasni12, 13, Kun Mu14, Hui Wang1, 2 and Jian Zhu1, 2, 15 1Research Center for Immunology, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China 2Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China 3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Renal cancer and Melanoma, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China 4Laboratory of Genetic Regulators in the Immune System, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China 5Synthetic Biology Remaking Engineering and Application Laboratory, School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, Henan, China 6Department of Gastroenterology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China 7Center for Cancer Research, Xinxiang Medical University, Xinxiang, Henan, China 8School of International Education, Xinxiang Medical University, Xinxiang, Henan, China 9Department of Medical Oncology, The First Affiliated Hospital, University of South China, Hengyang, Hunan, China 10Department of Cancer genomics, LemonData biotech (Shenzhen) Ltd, Shenzhen, Guangdong, China 11Phil Rivers Technology (Beijing) Ltd. China 12Institute of Biochemistry University of Balochistan, Quetta, Pakistan 13Department of Hematology and Transfusion Medicine, Lund University, Lund, Sweden 14Department of Pathology, School of Medicine, Shandong University, Jinan, Shandong, China 15Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA *Ting Zhuang, Sifan Yu and Lichen Zhang contribute equally to this study Correspondence to: Jian Zhu, email: jian.zhu@utsouthwestern.edu Ting Zhuang, email: zhuangting_83@qq.com Hui Wang, email: wanghui@xxmu.edu.cn Kun Mu, email: mukun@sdu.edu.cn Keywords: SHARPIN, ER alpha, breast cancer, ubiquitination, protein stability Received: May 17, 2017 Accepted: June 29, 2017 Published: August 19, 2017 ABSTRACT Estrogen receptor α is expressed in the majority of breast cancers and promotes estrogen-dependent cancer progression. In our study, we identified the novel E3 ubiquitin ligase SHARPIN function to facilitate ERα signaling. SHARPIN is highly expressed in human breast cancer and correlates with ERα protein level by immunohistochemistry. SHARPIN expression level correlates with poor prognosis in ERα positive breast cancer patients. SHARPIN depletion based RNA-sequence data shows that ERα signaling is a potential SHARPIN target. SHARPIN depletion significantly decreases ERα protein level, ERα target genes expression and estrogen response element activity in breast cancer cells, while SHARPIN overexpression could reverse these effects. SHARPIN depletion significantly decreases estrogen stimulated cell proliferation in breast cancer cells, which effect could be further rescued by ERα overexpression. Further mechanistic study reveals that SHARPIN mainly localizes in the cytosol and interacts with ERα both in the cytosol and the nuclear. SHARPIN regulates ERα signaling through protein stability, not through gene expression. SHARPIN stabilizes ERα protein via prohibiting ERα protein poly-ubiquitination. Further study shows that SHARPIN could facilitate the mono-ubiquitinaiton of ERα at K302/303 sites and facilitate ERE luciferase activity. Together, our findings propose a novel ERα modulation mechanism in supporting breast cancer cell growth, in which SHARPIN could be one suitable target for development of novel therapy for ERα positive breast cancer.

31 January 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DWDepeng Wang
Depeng Wang
WXWei Xu
Wei Xu
MHMinghua Huang
Minghua Huang
WMWei Ma
Wei Ma
YLYulu Liu
Yulu Liu
KMKun Mu
Kun Mu
Drug resistance occurs frequently in triple-negative breast cancer (TNBC) and leads to early relapse and short survival. Targeting the DNA damage response (DDR) has become an effective strategy for overcoming TNBC chemoresistance. CENPF (centromere protein) is a key regulator of cell cycle progression, but its role in TNBC chemotherapy resistance remains unclear. Here, we found that CENPF, which is highly expressed in TNBC, is associated with a poor prognosis in patients receiving chemotherapy. In addition, in vitro CENPF knockdown significantly increased adriamycin (ADR)-induced cytotoxicity in MDA-MB-231 cells and ADR-resistant cells (MDA-MB-231/ADR). Then, we demonstrated that CENPF targets Chk1-mediated G2/M phase arrest and binds to Rb to compete with E2F1 in TNBC. Considering the crucial role of E2F1 in the DNA damage response and DNA repair, a novel mechanism by which CENPF regulates the Rb-E2F1 axis will provide new horizons to overcome chemotherapy resistance in TNBC.

21 May 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
QZQiang Zhang
Qiang Zhang
LLLi-Yuan Liu
Li-Yuan Liu
FWFei Wang
Fei Wang
KMKun Mu
Kun Mu
ZYZhigang Yu
Zhigang Yu
Background: There has been a sharp increase in the incidence of breast cancer in China in recent years. A number of female physical characteristics, such as age at menarche, menopause, first birth and the duration of breastfeeding, have been linked to breast cancer, yet data on these factors in Chinese women is largely missing both for aggregate and age-specific data. Thus, the objective of this study was to explore changes in female menstrual and childbearing characteristics as a possible explanation for increasing rates of breast cancer in this country. Method: From July to September 2008, a population based cross-sectional breast cancer survey covering 124,758 females from 4 provinces or cities in Eastern China was carried out, using multi-stage and cluster methods. In-person interviews based on a self-designed structured questionnaire were performed, in which female physiological and reproductive factors, such as age at menarche and menopause, menstrual cycle history, childbearing history, breastfeeding methods, abortions or miscarriage, were included. For every 10-year age category, the subjects were divided, and across those age groups, all the above factors were compared respectively and changes in physical and childbearing characteristics were evaluated. ANOVA was used to compare the differences across the groups. Results: A total of 122058 subjects were included in the final analysis. The mean age at menarche was 15.39 years, the mean number of full-term pregnancies was 1.58, the mean duration of breastfeeding was 22.68 months, the mean age at first birth was 23.75 years, the mean frequency of miscarriage was 0.36, and the mean age at menopause was 48.63 years. Significant differences across the several age groups were noted for the age at menarche, number of full-term pregnancies, accumulated duration of breastfeeding, age at first birth, number of miscarriages, and age at menopause. These data clearly showed a gradual shift towards an earlier age at menarche, fewer pregnancies and shorter breastfeeding lengths. Conclusions: Significant changes in female physical and childbearing characteristics across a number of different age ranges were detected. These changes may be related to the increasing trend of breast cancer in China.